Abstract
The tumour suppressor complex BRCA1–BARD1 functions in the repair of DNA double-stranded breaks by homologous recombination. During this process, BRCA1–BARD1 facilitates the nucleolytic resection of DNA ends to generate a single-stranded template for the recruitment of another tumour suppressor complex, BRCA2–PALB2, and the recombinase RAD51. Here, by examining purified wild-type and mutant BRCA1–BARD1, we show that both BRCA1 and BARD1 bind DNA and interact with RAD51, and that BRCA1–BARD1 enhances the recombinase activity of RAD51. Mechanistically, BRCA1–BARD1 promotes the assembly of the synaptic complex, an essential intermediate in RAD51-mediated DNA joint formation. We provide evidence that BRCA1 and BARD1 are indispensable for RAD51 stimulation. Notably, BRCA1–BARD1 mutants with weakened RAD51 interactions show compromised DNA joint formation and impaired mediation of homologous recombination and DNA repair in cells. Our results identify a late role of BRCA1–BARD1 in homologous recombination, an attribute of the tumour suppressor complex that could be targeted in cancer therapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Narod, S. A. & Foulkes, W. D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4, 665–676 (2004)
Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer 12, 68–78 (2012)
Silver, D. P. & Livingston, D. M. Mechanisms of BRCA1 tumor suppression. Cancer Discov. 2, 679–684 (2012)
Prakash, R., Zhang, Y., Feng, W. & Jasin, M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb. Perspect. Biol. 7, a016600 (2015)
Sawyer, S. L. et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov. 5, 135–142 (2015)
Futreal, P. A. et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266, 120–122 (1994)
Godwin, A. K. et al. A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. Am. J. Hum. Genet. 55, 666–677 (1994)
Miki, Y. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66–71 (1994)
Savage, K. I. et al. Identification of a BRCA1–mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability. Mol. Cell 54, 445–459 (2014)
Kawai, S. & Amano, A. BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex. J. Cell Biol. 197, 201–208 (2012)
Chang, S. & Sharan, S. K. BRCA1 and microRNAs: emerging networks and potential therapeutic targets. Mol. Cells 34, 425–432 (2012)
Kleiman, F. E. & Manley, J. L. Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50. Science 285, 1576–1579 (1999)
Kleiman, F. E. & Manley, J. L. The BARD1–CstF-50 interaction links mRNA 3′ end formation to DNA damage and tumor suppression. Cell 104, 743–753 (2001)
Deng, C. X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 34, 1416–1426 (2006)
Schlacher, K., Wu, H. & Jasin, M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51–BRCA1/2. Cancer Cell 22, 106–116 (2012)
Hatchi, E. et al. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol. Cell 57, 636–647 (2015)
Scully, R. et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88, 265–275 (1997)
Moynahan, M. E., Chiu, J. W., Koller, B. H. & Jasin, M. Brca1 controls homology-directed DNA repair. Mol. Cell 4, 511–518 (1999)
Caestecker, K. W. & Van de Walle, G. R. The role of BRCA1 in DNA double-strand repair: past and present. Exp. Cell Res. 319, 575–587 (2013)
Wu, L. C. et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet. 14, 430–440 (1996)
Irminger-Finger, I. & Jefford, C. E. Is there more to BARD1 than BRCA1? Nat. Rev. Cancer 6, 382–391 (2006)
McCarthy, E. E., Celebi, J. T., Baer, R. & Ludwig, T. Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability. Mol. Cell. Biol. 23, 5056–5063 (2003)
Westermark, U. K. et al. BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks. Mol. Cell. Biol. 23, 7926–7936 (2003)
Laufer, M. et al. Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair. J. Biol. Chem. 282, 34325–34333 (2007)
Densham, R. M. et al. Human BRCA1–BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection. Nat. Struct. Mol. Biol. 23, 647–655 (2016)
Thai, T. H. et al. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum. Mol. Genet. 7, 195–202 (1998)
Ghimenti, C. et al. Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations. Genes Chromosom. Cancer 33, 235–242 (2002)
Ishitobi, M. et al. Mutational analysis of BARD1 in familial breast cancer patients in Japan. Cancer Lett. 200, 1–7 (2003)
Karppinen, S. M., Heikkinen, K., Rapakko, K. & Winqvist, R. Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer. J. Med. Genet. 41, e114 (2004)
Wu, J. Y. et al. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis. Int. J. Cancer 118, 1215–1226 (2006)
Symington, L. S. DNA repair: Making the cut. Nature 514, 39–40 (2014)
San Filippo, J., Sung, P. & Klein, H. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 77, 229–257 (2008)
Daley, J. M. & Sung, P. 53BP1, BRCA1, and the choice between recombination and end joining at DNA double-strand breaks. Mol. Cell. Biol. 34, 1380–1388 (2014)
Paull, T. T., Cortez, D., Bowers, B., Elledge, S. J. & Gellert, M. Direct DNA binding by Brca1. Proc. Natl Acad. Sci. USA 98, 6086–6091 (2001)
Simons, A. M. et al. BRCA1 DNA-binding activity is stimulated by BARD1. Cancer Res. 66, 2012–2018 (2006)
Zhao, W. et al. Promotion of BRCA2-dependent homologous recombination by DSS1 via RPA targeting and DNA mimicry. Mol. Cell 59, 176–187 (2015)
San Filippo, J. et al. Recombination mediator and Rad51 targeting activities of a human BRCA2 polypeptide. J. Biol. Chem. 281, 11649–11657 (2006)
Jensen, R. B., Carreira, A. & Kowalczykowski, S. C. Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 467, 678–683 (2010)
Qi, Z. et al. DNA sequence alignment by microhomology sampling during homologous recombination. Cell 160, 856–869 (2015)
Lee, J. Y. et al. Base triplet stepping by the Rad51/RecA family of recombinases. Science 349, 977–981 (2015)
Pellegrini, L. et al. Insights into DNA recombination from the structure of a RAD51–BRCA2 complex. Nature 420, 287–293 (2002)
Zhao, W. & Sung, P. Significance of ligand interactions involving Hop2–Mnd1 and the RAD51 and DMC1 recombinases in homologous DNA repair and XX ovarian dysgenesis. Nucleic Acids Res. 43, 4055–4066 (2015)
Kovalenko, O. V., Wiese, C. & Schild, D. RAD51AP2, a novel vertebrate- and meiotic-specific protein, shares a conserved RAD51-interacting C-terminal domain with RAD51AP1/PIR51. Nucleic Acids Res. 34, 5081–5092 (2006)
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012)
Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013)
Nakanishi, K. et al. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc. Natl Acad. Sci. USA 102, 1110–1115 (2005)
Xia, B. et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell 22, 719–729 (2006)
Pinder, J., Salsman, J. & Dellaire, G. Nuclear domain ‘knock-in’ screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing. Nucleic Acids Res. 43, 9379–9392 (2015)
Orthwein, A. et al. A mechanism for the suppression of homologous recombination in G1 cells. Nature 528, 422–426 (2015)
Bunting, S. F. et al. 53BP1 inhibits homologous recombination in brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243–254 (2010)
Sigurdsson, S., Trujillo, K., Song, B., Stratton, S. & Sung, P. Basis for avid homologous DNA strand exchange by human Rad51 and RPA. J. Biol. Chem. 276, 8798–8806 (2001)
Sung, P. Catalysis of ATP-dependent homologous DNA pairing and strand exchange by yeast RAD51 protein. Science 265, 1241–1243 (1994)
Zhao, W. et al. Mechanistic insights into the role of Hop2–Mnd1 in meiotic homologous DNA pairing. Nucleic Acids Res. 42, 906–917 (2014)
Wiese, C. et al. Promotion of homologous recombination and genomic stability by RAD51AP1 via RAD51 recombinase enhancement. Mol. Cell 28, 482–490 (2007)
Dignam, J. D., Lebovitz, R. M. & Roeder, R. G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11, 1475–1489 (1983)
Acknowledgements
We thank X. Yu, J. Parvin and G. Dellaire for providing materials. This work was supported by US National Institutes of Health grants ES007061, CA220123, CA168635, CA92584, ES021454, CA215990 and R35GM118026. J.B.S. was supported by an NIH fellowship (F31CA210663). W.Z. and P.S. were also supported by a Basser Innovation Award from the Basser Center for BRCA at Penn Medicine’s Abramson Cancer Center.
Author information
Authors and Affiliations
Contributions
W.Z. and P.S. conceived the study. W.Z., E.C.G., Y.X., G.M.K., C.W., and P.S. designed the experiments and analysed the data. W.Z., F.L., X.C., J.B.S., D.G.M., Y.K., C.J.M., T.R., W.W., C.S., L.L., J.J.-S. and R.B.J. generated key materials and executed the experiments. X.S. and Y.D. provided statistical analysis. W.Z. and P.S. wrote the paper with input from the other authors.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
Reviewer Information Nature thanks P. Cejka, R. Scully and the other anonymous reviewer(s) for their contribution to the peer review of this work.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
Extended Data Figure 1 Purification of BRCA1–BARD1 and mutant variants, and DNA binding properties of BRCA1–BARD1 and BRCA1–BARD11–142.
a, b, Schematics of BRCA1 (a) and BARD1 (b) and mutant variants of these proteins tested in this study. c, SDS–PAGE of purified BRCA1–BARD11–142 (lane 2), BRCA1–BARD1 (lane 3), BRCA1–BARD1AAE (lane 4), BRCA11–500–BARD1 (lane 5), BRCA11–500–BARD11–261 (lane 6) and BRCA11–500–BARD1∆163–261 (lane 7). Size markers were run in lane 1. d, SDS–PAGE of purified BRCA1–BARD1 (lane 2), BRCA1–BARD1∆123–162 (lane 3), BRCA1–BARD1K140N (lane 4) and BRCA1∆758–1064–BARD1 (lane 5). Size markers were run in lane 1. e, DNA binding test of BRCA1–BARD1 with a mixture of D-loop, DNA bubble and dsDNA. f, Quantification of data from experiments in e. Data are means ± s.d., n = 5. g, DNA binding test of BRCA1–BARD1 with a mixture of D-loop, dsDNA and ssDNA. h, Quantification of data from experiments in g. Data are means ± s.d., n = 4. i, DNA binding test of BRCA1–BARD11–142 with a mixture of D-loop, DNA bubble and dsDNA. j, Quantification of the results obtained with 32 nM of protein complexes in e and i. Data are means ± s.d., n = 3 (BRCA1–BARD11–142) or 5 (BRCA1–BARD1). **P < 0.01.
Extended Data Figure 2 DNA binding by BARD1.
a, BRCA1–BARD1 (5 nM) was incubated with radiolabelled D-loop (10 nM) and then the nucleoprotein complex was presented with an increasing concentration of unlabelled ssDNA, dsDNA, fork, bubble or D-loop as indicated. b, Quantification of data from experiments in a. Data are means ± s.d., n = 2 (ssDNA) or 3 (all other substrates). c, DNA binding test of BRCA11–500–BARD11–261 with a mixture of D-loop, dsDNA and ssDNA. d, DNA binding test of BRCA11–500–BARD1∆163–261 with a mixture of D-loop, dsDNA and ssDNA. e, Comparison of results obtained using 32 nM of BRCA1–BARD1 (from Extended Data Fig. 1g), BRCA11–500–BARD1 (from Extended Data Fig. 10a), BRCA11–500–BARD11–261 (from c) and BRCA11–500–BARD1∆163–261 (from d). Data are means ± s.d., n = 3 (BRCA11–500–BARD11–261 and BRCA11–500–BARD1∆163–261) or 4 (BRCA1–BARD1 and BRCA11–500–BARD1). **P < 0.01. f, SDS–PAGE of purified BARD1124–270. g, EMSA to test BARD1124–270 for binding to the D-loop, DNA bubble (Bubble), double-stranded DNA (dsDNA) and single-stranded DNA (ssDNA). h, Nucleoprotein complex consisting of BARD1124–270 (16 nM) and radiolabelled D-loop (10 nM) was challenged with an increasing concentration of unlabelled ssDNA, dsDNA, fork, DNA bubble or D-loop as indicated. i, Quantification of data from experiments in h. Data are means ± s.d., n = 3 (D-loop and ssDNA) or 4 (Bubble, RF and dsDNA).
Extended Data Figure 3 The RAD51 interaction attributes of BRCA1–BARD1.
a, Affinity pull-down to test for the interaction of RecA with BRCA1–BARD1 (B1–B1) via the Flag tag on BRCA1. The supernatant (S), wash (W) and eluate (E) fractions were analysed by SDS–PAGE and Coomassie blue staining. b, Affinity pull-down with Flag-tagged BRCA1–BARD1 (66 nM) and an increasing concentration of RAD51 (1, 2, 4 and 8 μM). The eluates from the pull-down experiment were analysed by SDS–PAGE with Coomassie blue staining. c, The amount of BRCA1–BARD1 and RAD51 in lanes 2–5 of b was quantified against known quantities of these protein species, run and stained in the same SDS polyacrylamide gel. Data are means ± s.d., n = 3. d, Affinity pull-down to test for the interaction of RAD51 with BRCA1–BARD1 with or without ethidium bromide (EB) being present. e, Far western analysis to examine RAD51D–XRCC2 (DX2), GST–DSS1 (DSS1) and BRCA1–BARD1 for RAD51 interaction. f, Schematic of the GST-tagged RAD51 fragments examined (top). Results from the pull-down experiment to test for interaction of BRCA1-BARD1 with the RAD51 fragments via the GST tag on the latter (bottom). RAD51 fragments and BRCA1 were revealed by immunoblot analysis using anti-GST or anti-Flag antibodies, respectively. g, GST pull-down assay to test for the interaction of the RAD51-T3 fragment with BRCA1–BARD1, BRCA11–500–BARD1 and BRCA1–BARD11–142. The RAD51 fragment, GST, BRCA1 and BARD1 were revealed by immunoblot analysis using anti-GST, anti-Flag or anti-His antibodies, respectively. h, GST pull-down assay to test for competition between BRCA1–BARD1 (198 nM) and BRCA2–DSS1 (66 nM) for RAD51 (1 μM); DSS1 was GST-tagged. RAD51, BRCA1 and BRCA2 were revealed by immunoblot analysis using antibodies specific for them.
Extended Data Figure 4 Lack of recombination mediator activity in BRCA1–BARD1 and species-specific enhancement of RAD51 recombinase by BRCA1–BARD1.
a, Schematic of the test for mediator activity of BRCA complex (BRCA1–BARD1 and BRCA2–DSS1). b, BRCA1–BARD1 and BRCA2–DSS1 were tested for recombination mediator activity with RPA-coated ssDNA as substrate. c, Quantification of data from experiments in b. Data are means ± s.d., n = 3. d, Schematic of the test for ssDNA targeting activity of BRCA complex (BRCA1–BARD1 and BRCA2–DSS1). e, BRCA1–BARD1 was tested alongside BRCA2–DSS1 for the ability to target RAD51 to ssDNA. f, Quantification of data from experiments in e. Data are means ± s.d., n = 3. g, Schematic of the D-loop assay. h, D-loop reactions were carried out with the indicated concentration of BRCA1–BARD1 and ATP as the nucleotide cofactor. i, Quantification of data from experiments in h. Data are means ± s.d., n = 3. j, BRCA1–BARD1 and Saccharomyces cerevisiae Rad54 (yRad54) were tested for their influence on D-loop formation catalysed by S. cerevisiae Rad51 (yRad51). k, Quantification of data from experiments in j. Data are means ± s.d., n = 3.
Extended Data Figure 5 Interplay between BRCA2–DSS1 and BRCA1–BARD1.
a, D-loop reactions performed with the indicated concentration of BRCA1–BARD1 (B1–B1), BRCA2–DSS1 (B2–D1), and order of addition of reaction components. b, Quantification of data from experiments in a. Data are means ± s.d., n = 3. NS, non-significant. c, D-loop reactions performed with the indicated concentration of BRCA1–BARD1, BRCA2–DSS1, and order of addition of reaction components. d, Quantification of data from experiments in c. Data are means ± s.d., n = 3. *P < 0.05; **P < 0.01. e, Pairwise distance distributions39 for Atto565-dsDNA bound to the RAD51–ssDNA filaments with or without BRCA1–BARD1. Data are means ± errors (determined by bootstrapping). f, BRCA1–BARD1 (100 and 200 nM) was tested with filaments of yRad51–ssDNA in synaptic complex assembly as assayed by protection against restriction digest. g, Number of dsDNA oligonucleotides bound by the RAD51–ssDNA filament without (n = 49) and with BRCA1–BARD1 (n = 54), BRCA1–BARD1AAE (n = 50) or BRCA11–500–BARD1 (n = 50). Data are means ± 95% confidence intervals. **P < 0.01.
Extended Data Figure 6 Identification of the RAD51 interaction domain in BRCA1–BARD1.
a, Schematic of the BRCA1 deletion variants37 examined in this study. b, Testing BRCA1 deletion variants alone or in complex with BARD1 for the ability to co-immunoprecipitate RAD51 from insect cell extracts using anti-Flag resin with Benzonase treatment. The immunoprecipitates were analysed by western blotting with antibodies against the Flag epitope (for BRCA1), the His6 epitope (for BARD1), or RAD51, as indicated. The cell extracts (10% of total) were probed for their RAD51 content. c, Quantification of data from experiments in b. Data are means ± s.d., n = 3. *P < 0.05; **P < 0.01. d, Summary of the RAD51 interaction ability of BARD1 truncation mutants, based on the pull-down analyses in e (for BRCA1–BARD1, BRCA11–500–BARD1 and BRCA11–500–BARD11–261), f (for BRCA11–500–BARD1, BRCA11–500–BARD11–261 and BRCA11–500–BARD11–122), g (for BRCA11–500–BARD1∆123–261, BRCA11–500–BARD1∆123–162, BRCA11–500–BARD11–261 and BRCA11–500–BARD11–162) and h (for BARD1123–162). In e, f and g, the eluates from the affinity resin were analysed by SDS–PAGE and Coomassie blue staining. In h, the interaction between RAD51 and GST–BARD1123–162 was tested by pull-down using glutathione resin. The input and eluate fractions were analysed by western blotting with antibodies against GST or RAD51, as indicated.
Extended Data Figure 7 Characterization of BRCA1–BARD1 mutants.
a, BRCA1–BARD1 (n = 3), BRCA1–BARD1AAE (n = 3), BRCA1–BARD1∆123–162 (n = 3), and BRCA1–BARD1K140N (n = 4) were tested for their DNA binding activity using a mixture of radiolabelled D-loop and dsDNA as substrates. b, Quantification of data from experiments in a. Data are means ± s.d. c, Wild-type and mutant variants of BRCA1–BARD1 (300 nM each) were tested for the ability to promote synaptic complex formation. d, Quantification of data from experiments in c. Data are means ± s.d., n = 3. e, Synaptic complex formation by RAD51–ssDNA filament with BRCA1–BARD1 (100 and 200 nM) and BRCA1∆758–1064–BARD1 (100 and 200 nM). f, Quantification of data from experiments in e. Data are means ± s.d., n = 6 (BRCA1–BARD1 with Mg2+ and ATP) or n = 2 (all other conditions). *P < 0.05; **P < 0.01.
Extended Data Figure 8 Role of BRCA1 and BARD1 in homologous recombination and RAD51 focus formation.
a, Western blot to verify the nuclear localization of endogenous BRCA1 and ectopically expressed Flag-SBP-tagged BARD1 or the AAE mutant in HeLa cells. The cytoplasmic (C) and nuclear (N) fractions were also analysed for their alpha-tubulin and histone H3 contents. b, Western blot analysis to detect endogenous BRCA1 and BARD1 after treatment of DR-U2OS cells with BRCA1 or BARD1 siRNA. c, Homologous recombination frequency in DR-U2OS cells with siRNA-mediated knockdown of BRCA1 or BARD1. Data are means ± s.d., n = 3. d, Gene-targeting efficiency of CRISPR–CAS9 in U2OS cells with siRNA-mediated knockdown of BRCA1 or BARD1. Data are means ± s.d., n = 3. e, Western blot analysis to detect endogenous BRCA1, BARD1 and BRCA2 after treatment of HeLa cells with siRNA against BRCA1, BARD1 or BRCA2. Alpha-tubulin serves as loading control. f, Representative micrographs of RAD51 foci (red) in the nuclei of HeLa cells treated with BRCA1, BARD1, BRCA2 or control siRNA 8 h after exposure to 4 Gy γ-rays. Blue, DAPI. g, Quantification of RAD51 foci at various time points after exposure to 4 Gy γ-rays or sham irradiation. The mean values ± s.e.m. of 4 (siBRCA2 and siBARD1), 6 (siBRCA1) or 7 (siControl) independent experiments are shown. h, Western blot analysis to detect endogenous BRCA1 and 53BP1 after treatment of DR-U2OS cells with BRCA1 or TP53BP1 siRNA. i, Homologous recombination frequency in DR-U2OS cells with siRNA-mediated knockdown of BRCA1 and/or TP53BP1. Data are means ± s.d., n = 3. j, Western blot analysis to detect endogenous BARD1 and 53BP1 after treatment of DR-U2OS cells with BARD1 and/or TP53BP1 siRNA. k, Homologous recombination frequency in DR-U2OS cells with siRNA-mediated knockdown of BARD1 or TP53BP1. Data are means ± s.d., n = 3. l, Western blot analysis to detect ectopically expressed and endogenous BARD1 after treatment of U2OS cells with BARD1 and/or TP53BP1 siRNA. As the abundance of ectopically expressed Flag-SBP-tagged wild-type and mutant BARD1 was lower than that of endogenous BARD1, we revealed it with anti-Flag antibodies in western blot analysis. m, Homologous recombination frequency in DR-U2OS cells treated with siRNA against BARD1 and/or TP53BP1 and stably expressing BARD1WTres or BARD1AAEres. Data are means ± s.d., n = 3. *P < 0.05; **P < 0.01; NS, non-significant.
Extended Data Figure 9 Characterization of human cells expressing BARD1 mutants.
a, Western blot analysis to detect ectopically expressed and endogenous BARD1 after treatment of U2OS cells with BARD1 or control siRNA for the experiments in Fig. 5b. b, Western blot analysis to detect ectopically expressed and endogenous BARD1 after treatment of U2OS cells with BARD1 or control siRNA for the experiments in Fig. 5c. c, Western blot analysis to detect ectopically expressed and endogenous BARD1 after treatment of HeLa cells with BARD1 or control siRNA for the experiments in Fig. 5d. In a–c, as the abundance of ectopically expressed Flag-SBP-tagged wild-type and mutant BARD1 was lower than that of endogenous BARD1, we revealed it with anti-Flag antibodies in western blot analysis. d, Representative micrographs of RAD51 foci (red) in the nuclei of HeLa cells expressing Flag-SBP-tagged BARD1WTres or BARD1AAEres 8 h after exposure to 4 Gy γ-rays. Blue, DAPI. e, Quantification of RAD51 foci at various time points after exposure to 4 Gy γ-rays or sham irradiation. The mean values ± s.e.m. of 5 (8-h time point) or 3 (all other time points) independent experiments are shown. NS, non-significant. f, Western blot to reveal pRPA32(S4/S8) (with tubulin as the loading control) at various time points (0, 24 and 72 h) after a 1-h treatment with 2 μM MMC.
Extended Data Figure 10 Characterization of BRCA11–500–BARD1 and BRCA1∆758–1064–BARD1.
a, BRCA11–500–BARD1 was tested for DNA binding using a mixture of radiolabelled D-loop, dsDNA, and ssDNA as substrates. b, Quantification of data from experiments in a. Data are means ± s.d., n = 4. c, Comparison of results obtained using 32 nM BRCA1–BARD1 (from Extended Data Fig. 1g) and BRCA11–500–BARD1 (from a). Data are means ± s.d., n = 3. NS, non-significant. d, BRCA1–BARD1 and BRCA1∆758–1064–BARD1 were tested for DNA binding using a mixture of radiolabelled D-loop, bubble, and dsDNA as substrates. e, Comparison of results obtained using 16 nM BRCA1–BARD1 and BRCA1∆758–1064–BARD1. Data are means ± s.d., n = 4. NS, non-significant. f, Far western analysis to detect RAD51 association with BRCA11–500 and BARD1 immobilized on nitrocellulose membrane. g, Pull-down assay to test for the interaction of RAD51 with BRCA11–500–BARD1, BRCA1–BARD11–142 and BRCA1–BARD1 via the Flag tag on the BRCA1 species. The eluates from the various anti-Flag resin fractions were subjected to immunoblot analysis with anti-Flag (for BRCA1), anti-His (for BARD1) and anti-RAD51 antibodies. h, Pull-down assay to test for the interaction between RAD51 and BRCA1–BARD1 or BRCA1∆758–1064–BARD1 via the Flag tag on the BRCA1 species. i, BRCA11–500–BARD1 and BRCA1∆758–1064–BARD1 were tested along with the wild-type complex for the ability to enhance RAD51-mediated D-loop formation. j, Quantification of data from experiments in i. Data are means ± s.d., n = 3 or 4. **P < 0.01.
Supplementary information
Supplementary Figures
This file contains figures and extended data figures. It also contains a figure exemplifying the gating strategy. (PDF 2266 kb)
Rights and permissions
About this article
Cite this article
Zhao, W., Steinfeld, J., Liang, F. et al. BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairing. Nature 550, 360–365 (2017). https://doi.org/10.1038/nature24060
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature24060
This article is cited by
-
FIGNL1 AAA+ ATPase remodels RAD51 and DMC1 filaments in pre-meiotic DNA replication and meiotic recombination
Nature Communications (2023)
-
RMI1 facilitates repair of ionizing radiation–induced DNA damage and maintenance of genomic stability
Cell Death Discovery (2023)
-
Mechanisms of synthetic lethality between BRCA1/2 and 53BP1 deficiencies and DNA polymerase theta targeting
Nature Communications (2023)
-
H3.1K27me1 loss confers Arabidopsis resistance to Geminivirus by sequestering DNA repair proteins onto host genome
Nature Communications (2023)
-
LncRNA CACClnc promotes chemoresistance of colorectal cancer by modulating alternative splicing of RAD51
Oncogene (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.